The FDA has approved a label update for Ibtrozi that incorporates extended response data.
The FDA has approved an updated label for Ibtrozi, adding extended response data to the prescribing information.
Further details on the nature of the extended response data and any implications for the product's approved uses were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
